The Oligonucleotide Synthesis Market is poised for robust growth, fueled by advancements in personalized medicine, molecular diagnostics, and genomics research. However, high production costs ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives.

Fintel reports that on June 17, 2025, Wolfe Research initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a ...

AOC delivers oligonucleotides synthesized from such RNA to cells with mutated genes. Existing RNA therapies have the same mechanism of action, but they have limitations in distinguishing target cells.

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by ...

Researchers from Waters and Biospring studied the contribution of nucleotide type and modifications on the retention and resolution of 22–24 nt long oligonucleotides in different chromatographic ...

SynaptixBio announces milestone with selection of candidate drug to treat rare disease H-ABC: Our Bureau, Bengaluru Friday, June 20, 2025, 12:30 Hrs [IST] Oxford-based SynaptixBio ...

Panelists discuss how recent advancements in muscular dystrophy treatment have evolved toward truly disease-modifying ...

Immunoglobulin A nephropathy (IgAN), or Berger’s disease, is a chronic kidney disorder characterized by deposition of IgA antibodies in the glomeruli, which leads to inflammation and progressive renal ...

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy ...

Ultimately, Stoke Therapeutics is that classic “intriguing biotech” --hurdling to one of those proverbial “moments of truth” ...